Papers: 10.1007/s12253-020-00809-z
https://doi.org/10.1007/s12253-020-00809-z
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Cited by: 4
Author(s): Lajos Gergely, G. Bodoky, György Rokszin, Ibolya Fábián, László Torday
Published: over 5 years ago
Software Mentions 3
Very Likely Science (100)
Very Likely Science (75)
Very Likely Science (90)